Proin Chewable Tablets for Dogs (25 mg, 50 mg, and 75mg)
A supplemental product for urinary incontinence in dogs. Each tablet contains phenylpropanolamine HCl (PPA), 25 mg.
Proin Chewable Tablets for Dogs is indicated for the control of urinary incontinence due to urethral sphincter hypotonus in dogs.
Dosage and Administration:
The total recommended dosage for oral administration is 2 mg/kg (0.91 mg/lb) of body weight twice daily. Proin is scored and dosage should be calculated in half-tablet increments.
Not for human use. Keep out of reach of children. Consult a physician in case of accidental ingestion by humans.
Proin may cause increased thirst; therefore, provide ample fresh water. Overdose has been associated with dogs chewing through closed bottles of Proin and consuming multiple tablets. Therefore, it is important to store Proin Chewable Tablets out of reach of dogs and other pets in a secured location.
Use in dogs with incontinence due to a urinary tract infection will mask symptoms. Proin is not effective in dogs with incontinence due to neurologic disease or malformations.
Proin may cause hypertension; therefore, use with caution in dogs with pre-existing heart disease, hypertension, liver disease, kidney insufficiency, diabetes, glaucoma, and conditions with a predilection for hypertension. Use with caution in dogs receiving sympathomimetic drugs, tricyclic antidepressants, or monoamine oxidase inhibitors as increased toxicity may result. Use with caution in dogs administered halogenated gaseous anesthetics as this may increase the risk of cardiac arrhythmias.
A laboratory study on human blood revealed that PPA used in conjunction with aspirin may potentiate decreased platelet aggregation. The safe use of Proin in dogs used for breeding purposes, during pregnancy or in lactating bitches, has not been evaluated.
Adverse Reactions “Pre Approval Experience”:
A placebo-controlled clinical study involving 123 Proin-treated dogs and 61 placebo-treated dogs was conducted for 28 days. The most common adverse reactions are shown in Table 1. In addition, one dog exhibited disorientation, nervousness, a 7.7% loss of body weight, and hypertension with proteinuria. A second dog exhibited restless behavior, lethargy, a 2.8% body weight loss, and proteinuria.